Launch of New Version of LiDCOrapid software at the 34th ESICEM Meeting

17 March 2014

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that it will be showcasing the new LiDCOrapidv2 Unity software version 2.03 at the 34th International Symposium on Intensive Care and Emergency Medicine ('ESICEM') from March 18 - 21. This conference is organised by the department of Intensive Care Emergency Medicine of Erasme University Hospital, Université Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine ('SIZ').

The meeting is held annually, starting in 1980, and has become established as one of the largest in its field, now attracting more than 6090 participants and over 500 oral presentations, this is one of the most significant critical care conferences in the world.

LiDCO's Unity software allows the connection to the LiDCOrapidv2 of modules to co-display CNSystems' continuous non-invasive blood pressure monitoring with Covidien's depth of anaesthesia parameter ('BISTM'). The new version of the Unity software adds additional functionality that significantly reduces the equipment set-up time to monitoring continuous non invasive blood pressure and cardiac output data. Additionally, all LiDCO monitors are now compatible with the newly released Philips IntelliBridge patient data interface. IntelliBridge connects to LiDCO devices via a specific Philips Intellibridge module and cable. In combination these new features make the LiDCOrapidv2 system even easier to use and importantly integrates the data into the hospital's patient information system.

LiDCO's advanced hemodynamic monitors can be now used widely throughout the hospital to provide better fluid and hemodynamic monitoring in any high-risk patient requiring such care. A study on the cost effectiveness from use of the LiDCOplus monitor, which enhances postoperative monitoring in ICUs, has recently been published by Ebm et Al in Critical Care Medicine*.The study showed that goal directed therapy (GDT) in the ICU was responsible for a saving of up to £2,631 per patient through reducing complications and length of stay following surgery compared to standard treatment regimens. The authors commented that the monitoring expense can be offset after less than two months when 100 patients per year receive GDT through savings due to lower costs accrued from a reduction in complication rates and hospital length of stay for patients on GDT.

Commenting, Terry O'Brien, Chief Executive Officer of LiDCO, said:"The delivery of the new version of the LiDCOrapidv2 software with enhanced utility and connectivity will help establish LiDCO monitors as the products of choice for the monitoring many more of the 10 million patients worldwide which the Company estimates are suitable for peri-operative hemodynamic monitoring. Wider adoption and use of our technology to optimise the high-risk surgery patient's circulation will save money for healthcare providers and markedly improve outcomes."

Find us at the ESICEM, Brussels at stand 1.21-1.24 in hall 1.

* Paper Referenced: Ebm C, Cecconi M, Sutton L, Rhodes A (2014) A Cost-Effectiveness Analysis of Postoperative Goal-Directed Therapy for High-Risk Surgical Patients DOI: 10.1097/CCM0000000000000164

For further information, please contact:

LiDCO Group Plc www.lidco.com
Terry O'Brien (CEO)
Paul Clifford (Finance Director)
Tel: +44 (0)20 7749 1500


FinnCap
Geoff Nash / Henrik Persson (Corporate Finance)
Stephen Norcross (Corporate Broking)
Tel: +44 (0)20 7220 0500

Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Paul McManus
Lianne Cawthorne
Mob: 07980 541 893
Mob: 07584 391 303

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

  • early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
  • quantification of hemodynamic response
  • guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapidv2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

*BISTM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.

distributed by